PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Negative revenue growth while AXSM stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-57.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
5.53%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
5.53%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
5.62%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
13.79%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.79%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.10%
Share count expansion well above AXSM's 0.44%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above AXSM's 0.44%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
OCF growth above 1.5x AXSM's 6.69%. David Dodd would confirm a clear edge in underlying cash generation.
17.73%
FCF growth above 1.5x AXSM's 6.73%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
94.36%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
80.21%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-551.14%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
94.20%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
81.22%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
1992.70%
Equity/share CAGR of 1992.70% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
-67.70%
Negative 5Y equity/share growth while AXSM is at 4.25%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-15.48%
Negative 3Y equity/share growth while AXSM is at 154.65%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.08%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-0.47%
We cut SG&A while AXSM invests at 45.30%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.